TOCILIZUMAB

tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices

TOCILIZUMAB (11750K)

tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL pen devices
11750K
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Continuing treatment

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 4 # of repeats: 5 DPMQ: $801.70 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra ACTPen